News Under pressure, Novo lays out blockbuster launch plans Novo has revealed a plan to launch five or more blockbusters between now and 2030 that it hopes will grow annual revenues by around $23bn.
News CHMP backs Novo's haemophilia A drug Frehemgo Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.
News Novo taps Anthropic's Claude AI for drug discovery Novo adds Anthropic AI models and Claude Science to its drug discovery toolkit in a bid to become "the world's most AI-driven healthcare company."
News Novo Nordisk rebrands as Novo as new CEO charts turnaround Embroiled in a fight to retain market share in weight loss and diabetes therapies, Novo Nordisk has rebranded and launched a new corporate culture.
News Novo Nordisk's IL-6 drug flunks two more heart trials Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.
News Novo Nordisk partners Amazon on London AI hub Novo Nordisk has joined forces with Amazon Web Services on a project that will lead to the creation of an AI co-innovation hub in London.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.